Classes
DEA Class; Rx
Common Brand Names; Enlon Plus
- Antidotes, Systemic
Description
Combined cholinesterase inhibitor, edrophonium, and antimuscarinic agent, atropine
Used IV to reverse the effects of nondepolarizing neuromuscular blocking agents (e.g., curare type)
Edrophonium exerts the primary actions, while atropine decreases the adverse reactions associated with edrophonium
Indications
For use in nondepolarizing neuromuscular blockade reversal or antagonism, or as an adjunctive treatment of respiratory depression due to curare overdosage.
Contraindications
Glaucoma, posterior synechiae, synechia
GI obstruction, pyloric stenosis, toxic megacolon
Sulfite hypersensitivity
Adverse Effects
AV block
Bradycardia
Arrhythmia exacerbation
Respiratory arrest
Laryngospasm
Seizures
Scarlatiniform Exanthema
Premature ventricular Contractions (PVCs)
Sinus tachycardia
Dysphonia
Dysarthria
Dysphagia
Conjunctival hyperemia
Photophobia
Blurred vision
Urinary retention
Bronchial secretions
Restlessness
Weakness
Asthenia
Abdominal pain
Vomiting
Nausea
Diarrhea
Pregnancy and Lactation
Atropine; edrophonium is classified as FDA pregnancy risk category C
According to the manufacturer, the safety and efficacy of atropine; edrophonium during breast-feeding has not been established.
Maximum Dosage
0.014 mg atropine; 1 mg edrophonium per kg IV per dose.
0.014 mg atropine; 1 mg edrophonium per kg IV per dose.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
